Proactive Investors - Run By Investors For Investors

Cellectar shares extend last Friday's 400% surge

Cellectar Biosciences shares advance by 20% - extending in small measure on the 400% leap seen on Friday after its phospholipid ether analogs as cancer-targeting drug vehicles received their US Patent and Trademarks
Cellectar shares extend last Friday's 400% surge
Patents received give boost

Cellectar Biosciences Inc (NASDAQ:CLRB) shares advanced by 20% on Monday - extending in small measure on the 400% leap seen on Friday.

Investors became excited last week that Cellectar's phospholipid ether analogs as cancer-targeting drug vehicles had received their US Patent and Trademarks.

The latest surge in the share price followed news that Cellectar chief executive, Jim Caruso, would be presenting at the 2016 Marcum MicroCap Conference in New York on 2 June.

Caruso intends to use the conference as a platform to publicise the group's phospholid drug conjugate platform.

The shares were last seen up 19.6% at $4.13.

View full CLRB profile View Profile

Cellectar Biosciences Timeline

Related Articles

Kazakhstan
November 20 2018
Borko Moric will succeed Parilla as chief executive officer. Bojan Moric will become the company's chief operations officer
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use